Glaucoma: Epidemiology Forecast to 2030

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

This report provides an overview of the risk factors, comorbidities, and the global and historical trends for glaucoma in the seven major markets: (7MM: The US, France, Germany, Italy, Spain, the UK, and Japan). In the 7MM, the total prevalent cases of primary open-angle glaucoma (POAG) will be 7,289,907 cases in 2020 growing at an Annual Growth Rate (AGR) of more than 2%. It is forecasted that all markets will see an increase in the total prevalent cases of POAG and PACG during the forecast period.

Glaucoma is a common, asymptomatic group of eye diseases that causes damage to the eye’s optic nerve, resulting in progressive, irreversible vision loss. Glaucoma is one of the leading causes of blindness worldwide, especially in elderly people. It is generally categorized as open-angle glaucoma (OAG), angle-closure glaucoma (ACG), or secondary glaucoma (SG). Although there are many types of glaucoma, the two most important types are OAG and ACG, with OAG accounting for approximately 80-90% of all glaucoma cases. OAG and ACG can also be classified as primary (primary open-angle glaucoma [POAG] or primary angle-closure glaucoma [PACG], respectively) or SG, depending on the cause.

In 2020, the US accounted for more than 30% of the total prevalent cases of NTG in the 7MM, with 2,909,797 cases. There were 2,480,076 cases of NTG in the 5EU combined of the cases in the 7MM in 2020. In 2020, Japan had 2,774,440 total prevalent cases, in the 7MM. In the 7MM, the number of total prevalent cases will grow at an Annual Growth Rate (AGR) of more than 0.50% cases by 2030.

Overview of Total Prevalent Cases of NTG, Men and Women, 7MM

Overview of Total Prevalent Cases of NTG, Men and Women, 7MM

For more insights on this report, download a free report sample

What are the market dynamics in the glaucoma epidemiology?

Glaucoma is a serious burden on health resources, and due to the rapidly aging population with comorbidities across countries, this is expected to increase further in the future. Studies have suggested that the prevalence of glaucoma (especially POAG) has been steadily increasing over the past decade but ascertaining this is difficult due to most cases remaining undiagnosed. It’s been expected that all markets will see an increase in the total prevalent cases and diagnosed prevalent cases of POAG and PACG during the forecast period.

There is also a general trend of the number of glaucoma cases increasing with age across the 7MM. There could be many reasons for the increasing prevalent cases, including a growing aging population, individuals with more comorbid conditions that worsen susceptibility, and asymptomatic cases that are detected at advanced levels or stages. Glaucoma blindness has increased even if the treatment on offer prevents the worsening of eye conditions. The primary reason for this is that most of the cases remain undiagnosed. The older population is at higher risk of glaucoma, and epidemiologists forecast that ages 70 years and older represent 60% of all POAG cases. This age group also has more comorbidities than younger age groups. Thus, patient management should rely on early recognition of at-risk patients (aging population with comorbidities), allowing correct therapeutic measures to be started rapidly.

Which are the key countries in the glaucoma epidemiology market?

In the 7MM, the US had the highest total prevalence of POAG in 2020 in men, whereas Japan had the lowest total prevalence in 2020. In the 7MM, France had the highest total prevalence of POAG in 2020 in women whereas Japan had the lowest total prevalence in 2020. The difference in prevalence between men and women was highest in France with the prevalence of POAG in women 0.85% higher than in men.

Similarly, in the 7MM, Japan had the highest total prevalence of PACG in 2020 in men whereas, the US had the lowest total prevalence in 2020. In the 7MM, Japan had the highest total prevalence of PACG in 2020 in women, whereas the US had the lowest total prevalence in 2020r. The difference in prevalence between men and women was highest in Italy with prevalence in women 0.72% higher than in men.

Glaucoma epidemiology market, by key country

Glaucoma epidemiology market, by key country

For more about regional insights, download a free report sample

Market report scope

Total Prevalent Cases of NTG (7MM) 2,909,797 cases
Growth rate AGR of >1%
Forecast Period 2020-2030
Key Countries The US, France, Germany, Italy, Spain, the UK, and Japan

Scope

  • Glaucoma Epidemiology Report and Model provide an overview of the risk factors and global trends of glaucoma in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • This report also includes a 10-year epidemiological forecast for the following segmentations in ≥40 years the 7MM: total prevalent cases and diagnosed prevalent cases of primary open-angle glaucoma (POAG) and primary angle-closure glaucoma (PACG), segmented by sex and age (40–49 years, 50–59 years, 60–69 years, 70–79 years, and ages 80 years and older). In addition, this report also provides a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of following glaucoma clinical types: normal-tension glaucoma (NTG), pre perimetric glaucoma (PPG), and secondary glaucoma (SG). The report also includes the diagnosed incident cases of acute PACG and diagnosed prevalent cases of acute and chronic PACG.
  • The Glaucoma Epidemiology Report and Model were written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
  • The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

  • Develop business strategies by understanding the trends shaping and driving the global glaucoma market.
  • Quantify patient populations in the global glaucoma market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying by identifying the age groups and sex that present the best opportunities for therapeutics in each of the markets covered.
  • Understand the population of glaucoma clinical types such as POAG, PACG, NTG, PPG, and SG.

Table of Contents

| Contents

| List of Tables

| List of Figures

| About GlobalData

1 Glaucoma: Executive Summary

1.1 Catalyst

1.2 Related Reports

1.3 Upcoming Reports

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global and Historical Trends

2.4 Forecast Methodology

2.4.1 Sources

2.4.2 Forecast Assumptions and Methods

2.4.3 Total Prevalent Cases of POAG

2.4.4 Total Prevalent Cases of PACG

2.4.5 Total Prevalent Cases of NTG and PPG

2.4.6 Total Prevalent Cases of SG

2.4.7 Diagnosed Prevalent Cases

2.4.8 Diagnosed Incident Cases of Acute PACG

2.5 Epidemiological Forecast for Glaucoma (2020–2030)

2.5.1 Total Prevalent Cases of POAG

2.5.2 Age-Specific Total Prevalent Cases of POAG

2.5.3 Sex-Specific Total Prevalent Cases of POAG

2.5.4 Total prevalent Cases of PACG

2.5.5 Age-Specific Total Prevalent Cases of PACG

2.5.6 Sex-Specific Total Prevalent Cases of PACG

2.5.7 Total Prevalent Cases of NTG

2.5.8 Total Prevalent Cases of SG

2.5.9 Total Prevalent Cases of PPG

2.5.10 Diagnosed Prevalent Cases of POAG

2.5.11 Diagnosed Prevalent Cases of PACG

2.5.12 Diagnosed Prevalent Cases of Acute and Chronic PACG

2.5.13 Diagnosed Incident Cases of Acute PACG

2.5.14 Diagnosed Prevalent Cases of NTG

2.5.15 Diagnosed Prevalent Cases of SG

2.5.16 Diagnosed Prevalent Cases of PPG

2.6 Discussion

2.6.1 Epidemiological Forecast Insight

2.6.2 COVID-19 Impact

2.6.3 Limitations of the Analysis

2.6.4 Strengths of the Analysis

3 Appendix

3.1 Bibliography

3.2 Primary Research – Prescriber Survey

3.3 About the Authors

3.3.1 Epidemiologist

3.3.2 Reviewers

3.3.3 Global Director of Therapy Analysis and Epidemiology

3.3.4 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

Table

Table 1: Summary of Newly Added Data Types and Countries

Table 2: Summary of Updated Data Types

Table 3: Risk Factors and Comorbidities for Glaucoma

Table 4: High-Prescribing Physicians (Non-KOLs), Surveyed by Country, 2021

Figures

Figure 1: 7MM, Total Prevalent Cases of POAG, Both Sexes, Ages ≥40 Years, 2020 and 2030

Figure 2: 7MM, Total Prevalent Cases of PACG, Both Sexes, Ages ≥40 Years, 2020 and 2030

Figure 3: 7MM, Total Prevalence of POAG, All Ages, Men and Women, Ages ≥40 Years, 2020

Figure 4: 7MM, Total Prevalence of PACG, All Ages, Men and Women, Ages ≥40 Years, 2020

Figure 5: 7MM, Sources Used and Not Used for Total Prevalent Cases of POAG

Figure 6: 7MM, Sources Used for Total Prevalent Cases of PACG

Figure 7: 7MM, Sources Used for Total and Diagnosed Prevalent Cases of NTG

Figure 8: 7MM, Sources Used for Total Prevalent Cases of PPG

Figure 9: 7MM, Sources Used for Total and Diagnosed Prevalent Cases of SG

Figure 10: 7MM, Sources Used for Diagnosed Prevalent Cases of POAG

Figure 11: 7MM, Sources Used for Diagnosed Prevalent Case of PACG

Figure 12: 7MM, Sources Used for Diagnosed Incident Cases of Acute PACG

Figure 13: 7MM, Total prevalent Cases of POAG, Men and Women, Ages ≥40 Years, N, 2020

Figure 14: 7MM, Age-Specific Total Prevalent Cases of POAG, Men and Women, N, 2020

Figure 15: 7MM, Sex-Specific Total prevalent Cases of POAG, Ages ≥40 Years, N, 2020

Figure 16: 7MM, Total prevalent Cases of PACG, Men and Women, Ages ≥40 Years, N, 2020

Figure 17: 7MM, Age-Specific Total Prevalent Cases of PACG, Men and Women, N, 2020

Figure 18: 7MM, Sex-Specific Total Prevalent Cases of PACG, Ages ≥40 Years, N, 2020

Figure 19: 7MM, Total Prevalent Cases of NTG, Men and Women, Ages ≥40 Years, N, 2020

Figure 20: 7MM, Total Prevalent Cases of SG, Men and Women, Ages ≥40 Years, N, 2020

Figure 21: 7MM, Total Prevalent Cases of PPG, Men and Women, Ages ≥40 Years, N, 2020

Figure 22: 7MM, Diagnosed Prevalent Cases of POAG, Men and Women, Ages ≥40 Years, N, 2020

Figure 23: 7MM, Diagnosed Prevalent Cases of PACG, Men and Women, Ages ≥40 Years, N, 2020

Figure 24: 7MM, Diagnosed Prevalent Cases of Acute and Chronic PACG, Men and Women, Ages ≥40 Years, N, 2020

Figure 25: 7MM, Diagnosed Incident Cases of Acute PACG, Men and Women, Ages ≥40 Years, N, 2020

Figure 26: 7MM, Diagnosed Prevalent Cases of NTG, Men and Women, Ages ≥40 Years, N, 2020

Figure 27: 7MM, Diagnosed Prevalent Cases of SG, Men and Women, Ages ≥40 Years, N, 2020

Figure 28: 7MM, Diagnosed Prevalent Cases of PPG, Men and Women, Ages ≥40 Years, N, 2020

Frequently asked questions

Glaucoma: Epidemiology Forecast to 2030 thematic reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Glaucoma: Epidemiology Forecast to 2030 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Glaucoma: Epidemiology Forecast to 2030 in real time.

  • Access a live Glaucoma: Epidemiology Forecast to 2030 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.